There is a newer version of this record available.

Working paper Open Access

Ivermectin for Covid-19

Sparavigna, Amelia Carolina

Discussion of scholar papers published until end of June and beginning of July, 2020,  on Ivermectin, and of news that we can find about its use for Covid-19.  A list of clinical trials is also given. For what concerns scholar papers, we report among them a preprint posted on 10 June in MedRχiv,  which concludes that Ivermectin was associated with lower mortality during treatment of Covid-19.  From news, we consider in particular the case of Iquitos,  capital city of the Loreto Region in Peru, where, by May 25, Covid-19 cases and deaths had dropped notably. The formulation of ivermectin used in Peru is also discussed, in particular that of the oral solution disclosed by the Peruvian Government. A section about updating (8 July) is added to the discussion.  We report also the preprint posted on 8 July in MedRχiv, showing the result of a clinical trial. The preprint tells in the conclusions that add-on use of Ivermectin is giving better results when compared to controls, in particular a significant shorter hospital stay.

Before reading this work, please consider that I am not a physician. I do not suggest the use of ivermectin. I am not touting this drug. This analysis of publications and news about ivermectin is made in the framework of a wider investigation about information concerning drugs used for Covid-19.
Files (287.7 kB)
Name Size
Ivermectin-11.pdf
md5:ab94d511edf4128622d9fd7b3f2b85c0
287.7 kB Download
3,881
1,311
views
downloads
All versions This version
Views 3,881196
Downloads 1,31174
Data volume 334.5 MB21.3 MB
Unique views 3,175170
Unique downloads 1,08965

Share

Cite as